MSB

5.85%

$1.09 mesoblast limited

Listening the the interview, GHVD looks to be a given, it is the...

First 38 Last

Share
Profile

Follow
cooper

684 Posts.

119

11/09/20

16:38

Post #: 47277285
Share

Originally posted by taylorstjames: ↑

Some crucial takeaways.

1) Still much looking forward to the FDA approval. Beyond GHVD they are looking at other indications!

2a) On GVHD - Hospitals can have Rem-L STOCKED day after approval. Looking at ~15 hospitals (as they do 50% of BMT)

2b) On reimbursements from insurance companies - starts DAY AFTER APPROVAL

SI - "We already have inventory, product is already made, and I don't see any reason why this product won't be used ASAP on FDA Approval"

3a) On C-19 ARDS trial interim results - Again, reiterated the case that the MOA of C-19 ARDS is very similar to MOA of GVHD. Just look at the compassionate use results in Mt Sinai!

Hopeful that label extension would be granted

3b) On the 30/45/60 interim results - "You're right that the interim analysis was just performed in the first 90 patients and we flew through that. The DSMB recommended that we continue with the trial..."

3c) On early stoppage - "We are focusing on completion of the trial and being in a position to present all the data to the FDA and have a potential label extension for Ryoncil "

3d) On Australia - Ethics approval = several hospitals in Melbourne and Sydney that will take part in the trial

4) On CHF & CLBP - "Both of these indications are really blockbuster unmet needs"

Again reiterated that its the same MOA of inflammation.

Mechanism is the same, different product, different delivery. Both readouts will happen 4th Quarter this year.

CHF - partnered with Tasly (in China), in USA anticipating to partner with a major heart failure company
CLBP - partnered with 'No.1 pain company' Grunenthal, waiting for EU P3 trial, USA also anticipating a partnership

5) On scaling up and COGS and QC -
a) Mentions Lonza, also acknowledges the much larger volume needed. Plans are already in place to increase production to meet need for C-19.
b) Mentions proprietary media using recombinant growth factors to increase yield by 5x-10x.
c) Mentions 3D-bioreactors increasing production and reduces the manual (labor) nature of the manufacturing

= reduced costs, increased volume production

6) On capacity to ramp up - they've been very judicious in terms of pre-launch capex (big pharma usually 18mths pre-approval), only invested 6mths in advance.

a) Mentions that - sales force is ready and 12mths worth of inventory is ready for launch

7) Capital - happy with capital position

8) On strategic partnership - Expects increase in royalties and also increase in revenue from strat partnerships

Expand

Listening the the interview, GHVD looks to be a given, it is the only way you could interpret SI's comment.

Picked this up off another site- https://www.fiercepharma.com/pharma/mesoblast-scores-fda-committee-s-backing-for-cell-therapy-despite-some-early-worries
In February 2018, Mesoblast posted pivotal phase 3 data in pediatric GVHD showing 69% of Ryoncil patients had a complete or partial response to the treatment after 28 days. The therapy is already approved as Temcell in Japan, where it is licensed to JCR Pharma.

MSB Price at posting: $4.49 Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 85 more messages in this thread...

First 38 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.09		Change 0.060(5.85%)		Mkt cap ! $1.238B

Open	High	Low	Value	Volume
$1.03	$1.10	$1.02	$6.406M	6.038M

Buyers (Bids)

No.	Vol.	Price($)
2	313712	$1.08

Sellers (Offers)

Price($)	Vol.	No.
$1.09	100000	1

View Market Depth

No.	Vol.	Price($)
2	313712	1.075
2	30301	1.070
1	20501	1.065
4	67600	1.050
2	25072	1.045

Price($)	Vol.	No.
1.090	100000	1
1.095	50814	5
1.100	72846	10
1.105	46185	4
1.110	29041	4

Last trade - 16.10pm 17/05/2024 (20 minute delay)


Last $1.08		Change 0.060 ( 5.29 %)
Open	High	Low	Volume
$1.03	$1.10	$1.02	928883
Last updated 15.59pm 17/05/2024 ?

MSB (ASX) Chart

Listening the the interview, GHVD looks to be a given, it is the...

Featured News

The home PC changed retail stores forever. Shekel Brainweigh can do it again

Week 20 Wrap: EU-to-China cargoes up 12% YTD; US CPI tame

Encounter pulls a rabbit out of the hat chasing copper at Sandover

Greentech and Anax team up to put Whim Creek copper hub on steroids

After long delays, Mantle Minerals kicks off drillrun for gold at Mt Berghaus

Pegmatites under glacial cover excite Cygnus in Quebec

Patagonia grows portfolio of REE and lithium-focused territory with exploration grants

Market Update: ASX dips with only materials afloat

Tambourah gets state govt grant for drilling at namesake gold project in WA

'Future in Aussie' Budget boost could turn IGO into a Cinderella stock

Buyers (Bids)

Sellers (Offers)

Featured News

Listening the the interview, GHVD looks to be a given, it is the...

Featured News

Top Stories

The home PC changed retail stores forever. Shekel Brainweigh can do it again

Week 20 Wrap: EU-to-China cargoes up 12% YTD; US CPI tame

Encounter pulls a rabbit out of the hat chasing copper at Sandover

Greentech and Anax team up to put Whim Creek copper hub on steroids

After long delays, Mantle Minerals kicks off drillrun for gold at Mt Berghaus

Pegmatites under glacial cover excite Cygnus in Quebec

Patagonia grows portfolio of REE and lithium-focused territory with exploration grants

Market Update: ASX dips with only materials afloat

Tambourah gets state govt grant for drilling at namesake gold project in WA

'Future in Aussie' Budget boost could turn IGO into a Cinderella stock

Buyers (Bids)

Sellers (Offers)

Featured News